Collateral for a security interest recorded Dec 28, 2023 (SWK Funding LLC).
Term ends Jul 29, 2030 · High confidence
20-year base term ends Jul 29, 2030
Held by Journey Medical Corporation
Filed Aug 22, 2018 as application 16/108,799 · Granted Jan 11, 2022
Base term plus 63 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2010
2030
Clock starts
Jul 29, 2010
Jul 29, 2010
Term ends
Jul 29, 2030
Jul 29, 2030
Granted
Jan 11, 2022
Jan 11, 2022
base term
fee events
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
63
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 9,167,813, US 9,572,775.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 63 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 1 of 2 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 29, 2010, when application PCT/IB2010/002241, the earliest non-provisional in its chain, was filed (this one was filed Aug 22, 2018) | Jul 29, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +63 days, USPTO patent term adjustment record | Sep 30, 2030 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,167,813, US 9,572,775) | capped to Jul 29, 2030 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jul 29, 2030 | High confidence |
Partial family
| Application PCT/IB2010/002241 | PCT application no patent term | no patent term |
| US 9,167,813 | In force Jul 2030 | Jul 2030 |
| US 9,572,775 | In force Jul 2030 | Jul 2030 |
| US 10,092,588 | Lapsed on the fee record Oct 2022 | Oct 2022 |
| US 11,219,631 | this patent Jul 2030 | Jul 2030 |
Partial: 1 of the 5 has no file history here, so its row comes from the patent's own record or names the application alone. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 21, 2018 Reel 47561, frame 931 | Tamarkin, Dov; Ziv, Enbal; Hazot, Yohan; Schuz, David | Foamix Ltd. | Assignment of Assignor's Interest |
| Nov 21, 2018 Reel 47617, frame 297 | Foamix, Ltd. | Foamix Pharmaceuticals, Ltd. | Change of Name |
| Jul 30, 2019 Reel 49912, frame 45 | Foamix Pharmaceuticals Ltd. | Perceptive Credit Holdings II, LP | Patent Security Agreement |
| Nov 4, 2020 Reel 54306, frame 387 | Foamix Pharmaceuticals Ltd. | Vyne Pharmaceuticals Ltd. | Change of Name |
| Feb 4, 2021 Reel 55215, frame 298 | Vyne Pharmaceuticals Ltd. | Vyne Therapeutics Inc. | Assignment of Assignor's Interest |
| Feb 17, 2021 Reel 55326, frame 9 | Vyne Therapeutics Inc. | Perceptive Credit Holdings II, LP | Patent Security Agreement |
| Sep 20, 2021 Reel 57544, frame 138 | Perceptive Credit Holdings II, LP | Vyne Pharmaceuticals Ltd. (F/K/A Foamix Pharmaceuticals Ltd.) | Release of Security Interest |
| Sep 20, 2021 Reel 57544, frame 708 | Perceptive Credit Holdings II, LP | Vyne Therapeutics Inc. (F/K/A Menlo Therapeutics Inc. and Successor-in-Interest to Vyne Pharmaceuticals Ltd., F/K/A Foamix Pharmaceuticals Ltd.) | Release of Security Interest |
| Dec 22, 2021 Reel 58463, frame 167 | Vyne Therapeutics Inc. | Vyne Pharmaceuticals Inc. | Assignment of Assignor's Interest |
| Feb 1, 2022 Reel 58925, frame 568 | Vyne Therapeutics Inc.; Vyne Pharmaceuticals Inc. | Journey Medical Corporation | Assignment of Assignor's Interest |
| Dec 28, 2023 Reel 66157, frame 79 | Journey Medical Corporation; JG Pharma, Inc. | SWK Funding LLC | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jul 2030
Term ends Jul 29, 2030. Maintenance fees still fall due before then
Note
The 63 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 9,167,813, US 9,572,775.
Citations
18
later US patents cite this one
That is top 5% of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.